Literature DB >> 1311063

Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor.

D Pim1, M Collins, L Banks.   

Abstract

We have until recently made several unsuccessful attempts to assign any activity to the human papillomavirus type 16 (HPV-16) E5 gene product. However, studies with the bovine papilloma virus 1 (BPV-1) E5 protein indicated an interaction with the epidermal growth factor receptor (EGFR). In light of the overall similarity between the HPV and BPV E5 proteins we attempted to determine whether the HPV-16 E5 gene had any common activity. In cells expressing high levels of EGFR plus HPV-16 E5 we found a dramatically increased proliferative activity in soft-agar assays in the presence of EGF. The specificity of this activity was monitored by the addition of other mitogenic agents. The phorbol ester phorbol 12-myristate 13-acetate (PMA) had no effect on the E5-containing cells, although insulin weakly stimulated their growth in soft agar. Further analysis revealed the same number of EGF receptors were present on the E5-containing cells as on the control cells, although the E5 cells were more sensitive to lower concentrations of EGF. These results imply that E5 is amplifying the mitogenic signals from the EGFR in an as yet unknown manner, but which may form the basis of interactions with a variety of growth factor receptors. This report brings to three the number of transforming genes encoded by HPV-16.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311063

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  75 in total

1.  Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.

Authors:  Frauke Fehrmann; David J Klumpp; Laimonis A Laimins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  HUMAN PAPILLOMAVIRUS ASSOCIATION WITH HEAD AND NECK CANCERS: UNDERSTANDING VIRUS BIOLOGY AND USING IT IN THE DEVELOPMENT OF CANCER DIAGNOSTICS.

Authors:  Katerina Strati; Paul F Lambert
Journal:  Expert Opin Med Diagn       Date:  2008-01-01

4.  Differential effects of the splice acceptor at nucleotide 3295 of human papillomavirus type 31 on stable and transient viral replication.

Authors:  D J Klumpp; F Stubenrauch; L A Laimins
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  A role for HPV16 E5 in cervical carcinogenesis.

Authors:  John P Maufort; Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

6.  Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion.

Authors:  Lulin Hu; Kendra Plafker; Valeriya Vorozhko; Rosemary E Zuna; Marie H Hanigan; Gary J Gorbsky; Scott M Plafker; Peter C Angeletti; Brian P Ceresa
Journal:  Virology       Date:  2008-11-28       Impact factor: 3.616

7.  E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line.

Authors:  Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky
Journal:  J Gen Virol       Date:  2018-04-06       Impact factor: 3.891

Review 8.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

Review 9.  Human papillomavirus infection with particular reference to genital disease.

Authors:  C Sonnex
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

10.  Mutational analysis of human papillomavirus type 11 E5a oncoprotein.

Authors:  S L Chen; T Z Tsai; C P Han; Y P Tsao
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.